C5AR1 and COVID-19: Similarly, the C5 complement inhibitor eculizumab was also identified to represent a valid therapeutic option, in agreement with recent evidence that the C5a-C5aR axis promotes severe lung inflammation in COVID-19 patients by mediating recruitment and activation of pro-inflammatory myeloid cells [53, 64].